<DOC>
	<DOCNO>NCT01580228</DOCNO>
	<brief_summary>This study conduct demonstrate superiority progression-free survival ( PFS ) dinaciclib compare ofatumumab chronic lymphocytic leukemia ( CLL ) participant del 17p overall population refractory either fludarabine treatment chemoimmunotherapy .</brief_summary>
	<brief_title>A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab Patients With Refractory Chronic Lymphocytic Leukemia ( P07714 )</brief_title>
	<detailed_description>Dinaciclib cyclin-dependent kinase ( CDK ) inhibitor , specific CDK 1 , 2 , 5 9 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Aged 18 year old Confirmed diagnosis Chronic Lymphocytic Leukemia ( CLL ) Fludarabine chemoimmunotherapy refractory disease define : fail respond relapse within 6 month complete fludarabine another purine analog alone combination regimen , fail respond chemoimmunotherapy relapse within 24 month complete therapy combination chemotherapy plus antiCD20 monoclonal antibody Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 , 1 , 2 Adequate organ function laboratory parameter Women childbearing potential currently sexually active must agree use medically accept method contraception become sexually active participate study Symptomatic brain metastasis primary central nervous system malignancy Treatment CYP3A4 inhibitor inducer within 1 week prior randomization , chemotherapy biologic therapy within 4 week prior randomization Known human immunodeficiency virus ( HIV ) infection know HIVrelated malignancy Participants clinically active hepatitis B C define disease require therapy Positive test glucose6 phosphate dehydrogenase ( G6PD ) deficiency Prior allogeneic bone marrow transplant Presence Richter 's transformation Indeterminate deletion 17p status Previous treatment ofatumumab , dinaciclib , CDK inhibitor Active autoimmune anemia thrombocytopenia unless stable , defined responsive corticosteroid standard therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>